NIH R01 · 2024
Mitogenic and Oncogenic Regulation of ERK/RSK Signaling
Cancer is the 2nd leading cause of death in the US. The advent of new treatments such as immunotherapy and targeted therapies have revolutionized the fight against cancer, and when combined with surgery, often result in significant positive therapeutic responses. Unfortunately, some tumor cells gain the ability to resist drug- and immune- therapies, which is often linked to their ability to metastasize. Indeed, metastasis ultimately underlies the majority of patient mortality by cancer. A major unmet need in oncology is the prediction and prevention of metastatic progression. Thus, understanding how tumor cells acquire metastatic potential and develop drug resistance is critical to…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.